INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.
Experienced management team with a proven track record.
Patented and leading science in the area of NK immunotherapy.
INKmune is an off-the-shelf product that allows patient’s NK cells to better see, target and kill cancer.
|Got a question?
858 964 3720
M - F 8am to 5pm PST